Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access

    ARTICLE

    Is ypTNM staging a comparable predictor as pTNM staging for survival in non-metastatic rectal cancer after preoperative chemoradiation therapy?

    JEN-PIN CHUANG1,2,3, HSIANG-LIN TSAI4,5, WEI-CHIH SU4,6,7, PO-JUNG CHEN4,6, CHING-WEN HUANG4,5, TSUNG-KUN CHANG4,6,7, YEN-CHENG CHEN4,6, CHING-CHUN LI4,8, YUNG-SUNG YEH4,9,10, TZU-CHIEH YIN4,5,11, JAW-YUAN WANG4,5,6,12,13,*

    Oncology Research, Vol.32, No.11, pp. 1723-1732, 2024, DOI:10.32604/or.2024.052098 - 16 October 2024

    Abstract Background: The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for patients receiving neoadjuvant chemoradiotherapy (NACRT). However, whether the prognostic value of the ypTNM staging system for rectal cancer is similar to that of the pTNM staging system remains unclear. This study was conducted to compare the ypTNM and pTNM staging systems in terms of their prognostic value for patients with nonmetastatic rectal cancer undergoing proctectomy. Material and Methods: This study was conducted at a large teaching… More >

  • Open Access

    ARTICLE

    Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer

    Vanita Noronha*, Kumar Prabhash*, Amit Joshi*, Vijay Maruti Patil*, Sanjay Talole, Dipti Nakti*, Arvind Sahu*, Srushti Shah, Sarbani Ghosh-Laskar§, Prachi S. Patil, Shaesta A. Mehta, Nirmala Jambhekar#, Abhishek Mahajan**, Nilendu Purandare††

    Oncology Research, Vol.23, No.4, pp. 183-195, 2015, DOI:10.3727/096504016X14537290676865

    Abstract There are little data on the efficacy and safety of taxane/platinum with definitive radiotherapy (RT) for esophageal/GEJ cancer. This article is a retrospective analysis of patients who received weekly paclitaxel 50 mg/ m2 and carboplatin AUC 2 with radical definitive RT for locally advanced esophageal/GEJ cancer. Between February 2011 and July 2014, 179 patients were included. The median age was 54 years. Ninety-two percent of patients had squamous histology. Mean RT dose was 58.7 Gy in 32 fractions over 53 days, with mean of six chemotherapy cycles. Fifty-six percent of patients developed ³grade 3 acute… More >

Displaying 1-10 on page 1 of 2. Per Page